Skip to main content
SpringerLink
Log in

Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: A randomized, double-blind study

  • Antiarrhythmic Agent
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

Safety and efficacy of propafenone and disopyramide for long-term maintenance of sinus rhythm after electrical cardioversion was studied in 56 patients with chronic altrial fibrillation (median arrhythmia duration, 5 months). After cardioversion, patients were randomly assigned to receive double-blind propafenone 300 mg tid (25 patients) or disopyramide 250 mg tid (31 patients). Downward dose adjustment was allowed in case of intolerable side effects. The endpoints were arrhythmia recurrence; and side effects not amenable to dose reduction. For patients randomized to propafenone (mean dose, 878±65 mg/day), 66% [95% confidence interval [(CI) 46–85%] and 55% (95% CI, 34–76%) remained in sinus rhythm at 3 and 6 months, respectively (Kaplan-Meier method). Similar figures were found with disopyramide (mean dose, 704±81 mg/day): 71% (95% CI, 54–87%) and 67% (95% CI, 50–84%) at 3 and 6 months, respectively (p=NS). In the patients with a relapse of atrial fibrillation, the ventricular rate while still using the prophylactic agents did not increase significantly compared with precardioversion. However, one patient on disopyramide had an excessively high relapse heart rate (170 vs. 100 beats/min). Side effects were more frequent on disopyramide. Side effects necessitating drug discontinuation occurred in 12 patients: 4 patients (16%) on propafenone and 8 (26%) on disopyramide. Severe adverse effects occurred in two patients, who developed heart failure while on disopyramide. There were no proarrhythmic events or deaths. Thus, propafenone and disopyramide are equally effective for maintaining sinus rhythm after cardioversion of atrial fibrillation. Propafenone is, however, better tolerated than disopyramide, which may cause heart failure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Härtel G, Louhija A, Konttinen A. Disopyramide in the prevention of atrial fibrillation after electroconversion.Clin Pharmacol Ther 1974;15:551–555.

    PubMed  Google Scholar 

  2. Södermark T, Edhag O, Sjögren A, et al. Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter: A multicenter study from Stockholm.Br Heart J 1975;37:486–492.

    PubMed  Google Scholar 

  3. Rasmussen K, Wang H, Fausa D. Comparative efficiency of quinidine and verapamil in the maintenance of sinus rhythm after DC conversion of atrial fibrillation. A controlled clinical trial.Acta Med Scand 1981;645(Suppl):23–28.

    Google Scholar 

  4. Lloyd EA, Gersh BJ, Forman R. The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation. A double-blind study comparing quinidine, disopyramide and placebo.S Afr Med J 1984;65:367–369.

    PubMed  Google Scholar 

  5. Gold RL, Haffajee CI, Charos G, Sloan K, Baker S, Alpert JS. Amiodarone for refractory atrial fibrillation.Am J Cardiol 1986;57:124–127.

    PubMed  Google Scholar 

  6. Karlson BW, Torstensson I, Abjörn C, Jansson SO, Peterson LE. Disopyramide in the maintenance of sinus rhythm after electrocardioversion of atrial fibrillation. A placebo controlled one-year follow-up study.Eur Heart J 1988;9:284–290.

    PubMed  Google Scholar 

  7. Juul-Möller S, Edvardsson N, Rehnqvlst-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation.Circulation 1990;82:1932–1939.

    Google Scholar 

  8. Karlson BW, Herlitz J, Edvardsson N, Olsson SB. Prophylactic treatment after electroconversion of atrial fibrillation.Clin Cardiol 1990;13:279–286.

    PubMed  Google Scholar 

  9. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion.Circulation 1990;82:1106–1116.

    Google Scholar 

  10. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation.J Am Coll Cardiol 1992; 20:527–532.

    PubMed  Google Scholar 

  11. Connoly SJ, Kates RE, Lebsack CS, Echt DS, Mason JW, Winkle RA. Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia.Am J Cardiol 1983;57:1208–1213.

    Google Scholar 

  12. Podrid PJ, Lown BL. Propafenone: A new agent for ventricular arrhythmia.J Am Coll Cardiol 1984;4:117–125.

    PubMed  Google Scholar 

  13. Connoly SJ, Mulji AS, Hoffert DL, Davis C, Shragge BW. Randomized placebo-controlled trial of propafenone for treatment of atrial tachyarrhythmias after cardiac surgery.J Am Coll Cardiol 1987;10:1145–1148.

    PubMed  Google Scholar 

  14. Kerr CR, Klein GJ, Axelson JE, Cooper JC. Propafenone for prevention of recurrent atrial fibrillation.Am J Cardiol 1988;61:914–916.

    PubMed  Google Scholar 

  15. Hammill SC, Wood DL, Gersh BJ, Osborn MJ, Holmes DR. Propafenone for paroxysmal atrial fibrillation.Am J Cardiol 1988;61:473–474.

    PubMed  Google Scholar 

  16. Antman EM, Beamer AD, Cantillon C, McGowan N, Goldman L, Friedman PL. Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter.J Am Coll Cardiol 1988;12:1005–1011.

    PubMed  Google Scholar 

  17. Porterfield JG, Porterfield LM. Therapeutic efficacy and safety of oral propafenone for atrial fibrillation.Am J Cardiol 1989;63:114–116.

    PubMed  Google Scholar 

  18. Connoly SJ, Hoffert DL. Usefulness of propafenone for recurrent paroxysmal atrial fibrillation.Am J Cardiol 1989; 63:817–819.

    PubMed  Google Scholar 

  19. Antman EM, Beamer AD, Cantillon C, McGowan N, Friedman PL. Therapy of refractory symptomatic atrial fibrillation and atrial flutter: A staged care approach with new antiarrhythmic drugs.J Am Coll Cardiol 1990;15:698–707.

    PubMed  Google Scholar 

  20. Kyles AE, Murdock CJ, Yeung-Lai-Wah JA, Vorderbrugge S, Kerr CR. Long-term efficacy of propafenone for prevention of atrial fibrillation.Can J Cardiol 1991;7:407–409.

    PubMed  Google Scholar 

  21. Reimold SC, Cantillon CO, Friedman PL, Antman EM. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation.Am J Cardiol 1993;71: 558–568.

    PubMed  Google Scholar 

  22. Van Gelder IC, Crijns HJGM, Van Gilst WH, De Langen CDJ, Van Wijk LM, Lie KI. Effects of flecainide on the atrial defibrillation threshold.Am J Cardiol 1989;63: 112–114.

    PubMed  Google Scholar 

  23. Van Gelder IC, Crijns HJGM, Van Gilst WH, Van Wijk LM, Hamer HPM, Lie KI. Efficacy and safety of flecainide in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter.Am J Cardiol 1989;64:1317–1321.

    PubMed  Google Scholar 

  24. Gosselink ATM, Crijns HJGM, Van Gelder IC, Hillege H, Wiesfeld ACP, Lie KI. Efficacy and safety of low dose amiodarone for long-term maintenance of sinus rhythm after electrical cardioversion of refractory chronic atrial fibrillation or flutter.JAMA 1992;267:3289–3293.

    PubMed  Google Scholar 

  25. Flecainide-Quinidine Research Group. Flecainide versus quinidine for treatment of chronic ventricular arrhythmias.Circulation 1983;67:1117–1123.

    Google Scholar 

  26. Robertson RE, Miller HC. Extreme tachycardia complicating the use of disopyramide in atrial flutter.Br Heart J 1980;44:602–603.

    PubMed  Google Scholar 

  27. Timm CT, Knowlton AA, Battinelli NJ, Falk RH. Flecainide for heart rate control in atrial fibrillation.J Am Coll Cardiol 1989;13:164A.

    Google Scholar 

  28. Podrid PJ, Schoeneberger A, Lown B. Congestive heart failure caused by oral disopyramide.N Engl J Med 1980; 302:614–617.

    PubMed  Google Scholar 

  29. Hoffmeister HM, Hepp A, Seipel L. Negative inotropic effects of class I antiarrhythmic drugs: Comparison of flecainide with disopyramide and quinidine.Eur Heart J 1987;8: 1126–1132.

    PubMed  Google Scholar 

  30. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.N Engl J Med 1989;321: 406–412.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Thoraxcenter, University Hospital, Groningen, The Netherlands

    Harry J. G. M. Crijns, A. T. Marcel Gosselink & Kong J. Lie

Authors
  1. Harry J. G. M. Crijns
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. T. Marcel Gosselink
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kong J. Lie
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Crijns, H.J.G.M., Gosselink, A.T.M. & Lie, K.J. Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: A randomized, double-blind study. Cardiovasc Drug Ther 10, 145–152 (1996). https://doi.org/10.1007/BF00823592

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00823592

Key words

Search

Navigation